

Advancing Early Psychosis Care in the United States

Addressing Inequities - Race, Culture, and COVID

**Psychopharmacology Management of Early Psychosis
During the COVID-19 Pandemic**

Session Bibliography

1. Kahl, K.G., & Correll, C.U. (2020). Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 Pandemic. *JAMA Psychiatry*, 77(9), 977.
2. Türközer, H.B., & Öngür, D. (2020). A projection for psychiatry in the post-COVID-19 era: potential trends, challenges, and directions. *Molecular Psychiatry*, 25(10), 2214-2219.
3. Bilbul, M., Paparone, P., Kim, A.M., Mutalik, S., & Ernst, C.L. (2020). Psychopharmacology of COVID-19. *Psychosomatics*, 61(5), 411-427.
4. Siskind, D., Honer, W.G., Clark, S., Correll, C.U., Hasan, A., Howes, O., ... & Freudenreich, O. (2020). Consensus statement on the use of clozapine during the COVID-19 pandemic. *Journal of Psychiatry and Neuroscience*, 45(3), 222-223.
5. Viani-Walsh, D., Kennedy-Williams, S., Taylor, D., Gaughran, F., & Lally, J.(in press). Vitamin D deficiency in schizophrenia implications for COVID-19 infection. *Irish journal of psychological medicine*. doi:10.1017/ipm.2020.107
6. Becker, W.C., & Fiellin, D.A. (2020). When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis. *Annals of Internal Medicine*, 173(1), 59-60.
7. Kozloff, N., Mulsant, B.H., Stergiopoulos, V., & Voineskos, A.N. (2020). The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. *Schizophrenia Bulletin*, 46(4), 752-757.